INS and type 2 diabetes mellitus: Glucagon-like peptide-1 (GLP-1) is an incretin that can decrease blood sugar levels in a glucose-dependent manner by enhancing insulin secretion; moreover, the action of GLP-1 is preserved in patients with type 2 diabetes, and substantial pharmaceutical research has therefore been directed towards developing GLP-1-based treatment.